TAR-200 Improves Survival in BCG-Unresponsive, Papillary High-Risk NMIBC

Fact checked by" Ashley Chan
News
Article

Data from cohort 4 of the phase 2 SunRISe-1 trial demonstrate durable DFS with TAR-200 in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Data from cohort 4 of the phase 2 SunRISe-1 trial demonstrate durable DFS with TAR-200 in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Data from cohort 4 of the phase 2 SunRISe-1 trial demonstrate durable DFS with TAR-200 in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

TAR-200 elicited durable disease-free survival (DFS) outcomes in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, papillary-only non-muscle-invasive bladder cancer (NMIBC), according to data from cohort 4 of the phase 2 SunRISe-1 trial (NCT04640623) presented at the 2025 American Urological Association Annual Meeting.1

Findings demonstrated that at a median follow-up of 12.8 months, patients treated with TAR-200 (n = 52) experienced a median DFS that was not reached (95% CI, 12.1-not estimable [NE]). The 6- and 9-month DFS rates were 85.3% (95% CI, 71.6%-92.7%) and 81.1% (95% CI, 66.7%-89.7%), respectively. Notably, only 5.8% of patients underwent radical cystectomy.

“DFS rates were consistently high across both [patients with] high-grade Ta and T1 [disease], indicative of this [intravesical drug–releasing] system, [TAR-200], increasing the penetration of the drug [gemcitabine] across the bladder wall,” lead study author Felix Guerrero-Ramos, MD, PhD, an attending urologist at Hospital Universitario 12 de Octubre in Madrid, Spain, said in a presentation of the data.

Behind TAR-200 and Cohort 4 of SunRISe-1

TAR-200 is a novel intravesical drug–releasing system intended to provide sustained delivery of gemcitabine through all layers of the bladder wall.

SunRISe-1 is a phase 2 study evaluating TAR-200 in patients with BCG-unresponsive, high-risk NMIBC. Patients who had carcinoma in situ (CIS) with or without papillary disease were randomly assigned to cohorts 1 to 3; those with papillary-only disease were assigned to cohort 4.

Patients with BCG-unresponsive, high-risk NMIBC with papillary disease and no CIS enrolled to cohort 4 also needed to have a persistent or recurrent disease within 12 months of completing BCG, and they needed to be unresponsive to BCG without receiving radical cystectomy.

All patients enrolled in cohort 4 received TAR-200 monotherapy. The primary end point for this cohort was DFS; safety and tolerability were key secondary end points.

The median age at enrollment for cohort 4 was 71.0 years (range, 42-88); the majority of patients were male (71.2%), White (86.5%), and had an ECOG performance status of 0 (94.2%). Additionally, 55.8% of patients were former smokers, 13.5% were current smokers, and 30.8% were never smokers.

All patients had papillary disease that was stage Ta (59.6%) or stage T1 (40.4%). Patients received a median of 12 prior doses of BCG (range, 8-45), and the median time from the last dose of BCG to diagnosis of high-grade papillary disease was 2.8 months (range, 0.3-9.9). Prior to enrollment, 82.4% of patients had declined a radical cystectomy, and 17.6% were ineligible.

Additional Efficacy and Safety Data

When analyzed by disease stage, patients with high-grade Ta disease (n = 31) achieved 6- and 9-month DFS rates of 85.7% (95% CI, 66.3%-94.4%) and 82.1% (95% CI, 62.3%-92.1%), respectively. Among patients with T1 disease (n = 21), these respective rates were 84.7% (95% CI, 59.7%-94.8%) and 79.4% (95% CI, 54.0%-91.7%).

In the overall population, the median progression-free survival (PFS) and overall survival (OS) were both NE. The respective 9-month PFS and OS rates were 95.6% (95% CI, 83.5%-98.9%) and 98.0% (95% CI, 86.4%-99.7%). Only 1 patient experienced disease progression to MIBC.

Regarding safety, the majority of treatment-emergent adverse effects (AEs) were grade 1 or 1 and resolved after a median of 3.7 weeks. Serious treatment-related AEs (TRAEs) occurred in 5.8% of patients, and TRAEs led to treatment discontinuation in 7.7% of patients. No treatment-related deaths were reported.

Any-grade TRAEs occurred in 80.8% of patients, and the incidence of grade 3 or higher TRAEs was 13.5%. The most common TRAEs included dysuria (any-grade, 40.4%; grade ≥3, 0%), pollakiuria (30.8%; 0%), micturition urgency (26.9%; 0%), urinary tract infection (23.1%; 1.9%), hematuria (13.5%; 0%), bladder pain (9.6%; 3.8%), nocturia (9.6%; 0%), bladder spasm (7.7%; 0%), noninfective cystitis (7.7%; 0%), pruritus (7.7%; 0%), asthenia (5.8%; 0%), bladder irritation (5.8%; 0%), pelvic pain (5.8%; 1.9%), urinary incontinence (5.8%; 1.9%), and urinary tract pain (5.8%; 0%).

The ongoing phase 3 SunRISe-5 trial (NCT06211764) is evaluating TAR-200 vs intravesical chemotherapy in patients with BCG-unresponsive or -experienced, high-risk NMIBC with papillary-only disease.

“[SunRISe-5] will provide further evidence on the potential role of TAR-200 in this setting,” Guerrero-Ramos concluded.

In January 2025, the FDA received a new drug application seeking the approval of TAR-200 for the treatment of patients with BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors, based on prior data from SunRISe-1.2

Disclosures: Guerrero-Ramos reported receiving grants/research funding from Combat Medical and Roche; consulting/advisory fees from AstraZeneca, Bristol Myers Squibb, Combat Medical, Janssen, Johnson & Johnson, Nucleix, Pfizer, and Roche; honoraria/speaker fees from Astellas, AstraZeneca, Bristol Myers Squibb, Combat Medical, Janssen, Merck, Nucleix, Palex, and Pfizer; and travel support from AstraZeneca, Ipsen, Janssen, and Pfizer.

References

  1. Guerrero-Ramos F, Jacob JM, Van der Heijden MS, et al. TAR-200 monotherapy in patients with bacillus Calmette-Guerin–unresponsive papillary disease–only high-risk non–muscle-invasive bladder cancer: first results from Cohort 4 of SunRISe-1. Presented at: 2025 AUA Annual Meeting; April 26-29, 2025; Las Vegas, NV.
  2. New drug application initiated with US FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. News release. Johnson & Johnson. January 15, 2025. Accessed April 26, 2025. https://www.investor.jnj.com/news/news-details/2025/New-Drug-Application-initiated-with-U.S.-FDA-for-TAR-200-the-first-and-only-intravesical-drug-releasing-system-for-patients-with-BCG-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/default.aspx
Recent Videos
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.